252 related articles for article (PubMed ID: 31147927)
1. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
2. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
3. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
4. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
5. Low levels of PSMA expression limit the utility of
Campbell SP; Baras AS; Ball MW; Kates M; Hahn NM; Bivalacqua TJ; Johnson MH; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2018 Jan; 32(1):69-74. PubMed ID: 29067547
[TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
7. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
8. PSMA-Targeted
Gorin MA; Rowe SP; Hooper JE; Kates M; Hammers HJ; Szabo Z; Pomper MG; Allaf ME
Eur Urol; 2017 Jan; 71(1):145-146. PubMed ID: 27363386
[No Abstract] [Full Text] [Related]
9. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
10. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
11.
Currie GM; Trifunovic M; Liu J; Kim S; Gurney H
J Nucl Med Technol; 2022 Sep; 50(3):282-285. PubMed ID: 34750233
[TBL] [Abstract][Full Text] [Related]
12. Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Rowe SP; Gorin MA; Hammers HJ; Pomper MG; Allaf ME; Javadi MS
Clin Nucl Med; 2016 Jan; 41(1):83-5. PubMed ID: 26402128
[TBL] [Abstract][Full Text] [Related]
13.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
14. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
15. Detection of prostate cancer with
Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
17. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
18. Prospective Evaluation of
Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
[No Abstract] [Full Text] [Related]
19. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
20. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
